Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026
Lipopolysaccharide (LPS, batch number L6529) was acquired from Sigma
Sexual problems and distress in United States women: prevalence and correlates
Explore other treatments you might be interested in
US$ 25.43
US$ 26.88
US$ 21.14
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 27.15
